A phase II, randomized, controlled, partially-blind study to demonstrate immunogenicity and assess safety of GlaxoSmithKline (GSK) Biologicals’ pneumococcal vaccines (2830929A and 2830930A) administered as a 3-dose primary vaccination course during the first 6 months of life and as a booster dose at 12-15 months of age. - SPNG-009

GlaxoSmithKline Biologicals0 个研究点目标入组 940 人开始时间: 2012年2月13日最近更新: 2017年1月31日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: GlaxoSmithKline Biologicals
入组人数: 940

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) (LARs) can and will comply with the requirements of the protocol.
•A male or female between, and including 6 to 12 weeks (42-90 days) of age at the time of the first vaccination. In addition, the first pneumococcal and DTPa.HBV-IPV-Hib vaccination should be given in accordance with the official national recommendations for the immunisation schedule of infants.
•Written informed consent obtained from the parents/LAR(s) of the subject.
•Healthy subjects as established by medical history and clinical examination before entering into the study.
•Born after a gestation period of at least 36 weeks.
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 940
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

排除标准

•Child in care.
•Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
•Chronic administration of immunosuppressants or other immune-modifying drugs since birth.
•Planned administration/administration of a vaccine containing diphtheria toxoid, tetanus toxoid (except MenC-TT in Spain) or CRM197 and not foreseen by the study protocol during any time of the study period, or of any other vaccines not foreseen by the protocol in the period starting from 30 days before each dose and ending 30 days after each dose of vaccine(s), with the following exceptions:
•-Licensed influenza vaccines are always allowed, even if concomitantly administered with the study vaccines.
•-Licensed rotavirus vaccines are allowed if administered at least 7 days before or after each dose of study of vaccines.
•-Licensed MenC-TT vaccine is allowed in Spain and should be concomitantly administered with the study vaccine at around 2, 4 and 12-15 months of age.
•-In case an emergency mass vaccination for an unforeseen public health threat (e.g. a pandemic) is organised by the public health authorities, outside the routine immunization program, that vaccine can be administered at any time during the study period provided it is licensed and used according to its Summary of Product Characteristics or Prescribing Information and according to the local governmental recommendations.
•Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product
•Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination
•Family history of congenital or hereditary immunodeficiency.
•History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s).
•Major congenital defects or serious chronic illness, including Kawasaki’s syndrome.
•History of any neurological disorders or seizures, including conditions such as hypotensive-hyporesponsive episodes, encephalopathy and any convulsions (afebrile and febrile).
•Acute disease and/or fever at the time of enrolment.
•Administration of immunoglobulins and/or any blood products since birth or planned administration during study period.
•Previous vaccination against diphtheria, tetanus, pertussis, polio, H. influenzae type b.
•Previous vaccination against S. pneumoniae.
•History of or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio, H. influenzae type b disease.
•Any medical condition which might interfere with the assessment of the study objectives in the opinion of the investigator.

研究者

发起方

GlaxoSmithKline Biologicals

相似试验

进行中（未招募）

1 期

Immunogenicity and safety of two formulations of GSK Biologicals? pneumococcal vaccine (2830929A and 2830930A) when administered in healthy infants.

EUCTR2011-005743-27-ESGlaxoSmithKline Biologicals953

进行中（未招募）

不适用

EUCTR2011-005743-27-PLGlaxoSmithKline Biologicals940

进行中（未招募）

不适用

EUCTR2011-005743-27-DEGlaxoSmithKline Biologicals940

进行中（未招募）

1 期

A phase II, randomized, open, partially controlled study to evaluate the safety and immunogenicity of different formulations of a pandemic influenza vaccine candidate (split virus formulation adjuvanted with AS03) given following a two-administration schedule (21 days apart) in children between 3 and 9 years of age. - H5N1-009, H5N1-022 STG 009 cohort 2, H5N1-023 STG 009 cohort 3

EUCTR2006-001168-22-GBGlaxoSmithKline Biologicals405

已完成

不适用

Phase II multi-centre study to evaluate efficacy, safety, and immunogenicity of GMZ2 candidate malaria vaccine in children aged 12 to 60 monthsPaediatricsMalaria

PACTR2010060002033537Statens Serum Intitute1,840